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INTRODUCTION
Rhinitis and asthma usually occur together. There are increas-
ing evidences that allergic rhinitis (AR) may influence the
clinical course of asthma. AR patients without symptoms of
asthma such as episodic cough, dyspnea, and wheezing often
have bronchial hyperresponsiveness (BHR) to nonspecific
bronchoconstrictors such as methacholine or histamine (1, 2).
Methacholine responsiveness in the asthmatic range among
the patients with rhinitis is associated with variable airflow
obstruction and subclinical asthma (3). 
Putative mechanisms linking rhinitis to asthma are explained
by direct and indirect effects (4). The direct effects are naso-
bronchial reflex, postnasal drip of inflammatory cells and/or
mediators from the nose into the lower airways, and absorp-
tion of inflammatory cells and/or mediators from the nose
into the systemic circulation, and ultimately, the lung. The
indirect effects are nasal obstruction causing reduction in fil-
tration, humidification, and warming function of the nose (5).
Rhinitis patients showed a lower degree of bronchial sensitivi-
ty to allergen than asthmatics, but responded to allergen inhala-
tion with changes in airway inflammation and in maximal
response plateau, very similar to asthma subjects. These data
support the hypothesis that both allergic asthma and AR
belong to the same population, and that the differences in
symptoms depend on a quantitatively different response to
environmental allergen inhalation (5). Eosinophilic inflam-
mation may be present in subjects with AR and BHR even
when there are no symptoms of asthma (6).
To investigate the mechanism of connecting upper and lower
airway inflammation, we conducted methacholine challenge
test and nasal eosinophils on nasal smear to patients with AR.
MATERIALS AND METHODS
Study design
Patients were recruited between 1998 and 2000 from Seon-
am University Hospital. The first visit included history and
diagnostic testing procedures to verify inclusion and exclusion
criteria and a questionnaire for symptoms and medications
was given and physical examination was performed. After then,
nasal smear for eosinophils, skin prick tests (SPT), spirometry,
and methacholine provocation test were done. 
Subjects
The study was performed as a prospective controlled clinical
trial. A total of 35 patients (13 perennial AR with exacerbation
and 22 seasonal AR) was included. AR was defined as a posi-
tive answer to the question, “Do you have any symptoms such
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There are increasing evidences that allergic rhinitis (AR) may influence the clinical
course of asthma. We conducted methacholine challenge test and nasal eosinophils
on nasal smear to patients with allergic rhinitis in order to investigate the mecha-
nism of connecting upper and lower airway inflammation in 35 patients with AR
during exacerbation. The methacholine concentration causing a 20% fall in FEV1
(PC20) was used as thresholds of bronchial hyperresponsiveness (BHR). Thresholds
of 25 mg/dL or less were assumed to indicate BHR. All patients had normal pul-
monary function. Significant differences in BHR were detected in the comparison
of patients with cough or postnasal drip and without cough or postnasal drip. There
were significant differences of PC20 between patients with cough or postnasal
drip and those without cough or postnasal drip (3.41±3.59 mg/mL vs 10.2±1.2
mg/mL, p=0.001). The levels of total IgE were higher in patients with seasonal AR
than in patients with perennial AR with exacerbation (472.5±132.5 IU/L vs.
389.0±70.9 IU/L, p<0.05). Nasal eosinophils were closely related to log PC20
(r=-0.65, p<0.01). These findings demonstrated that nasal eosinophilic inflam-
mation might contribute to BHR in patients with AR.
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as sneezing, itching, coryza, and nasal obstruction?” and a
positive skin prick test (Allergopharma, Germany) response
to 1 or more of 55 inhalant allergens. The type of rhinitis, sea-
sonal or perennial was in agreement with the kind of sensitizing
allergen, seasonal or perennial. Seasonal AR patients were
currently exposed and symptomatic. All patients did not take
anti-allergic therapy during the study period. Exclusion criteria
were the history of bronchial asthma, the existence of any nasal
disease other than AR, pregnancy, any acute or inflammatory
disease, anti-allergic therapy such as antihistamines or topical
steroids at study entry, presence of parasitic infections, hyper-
eosinophilia, respiratory infection for 4 weeks prior to the
study. All subjects were informed and gave their consent before
starting the study. The ethics committee of Seonam Univer-
sity Hospital approved the study protocol. 
Recording of symptoms
The patients received a questionnaire to document their
symptoms of AR (e.g., rhinorrhea, itching, sneezing, nasal
obstruction). The severity of symptoms was scored individually
on an arbitrary scale from 0 to 3 (0=free of symptoms, 1=mild,
2=moderate, 3=severe symptoms). The total symptom scores
were calculated by adding up all scores.
Nasal swabs for eosinophils  
A nasal secretion sample was taken from both nasal cavities
by wiping the surface of the inferior turbinate with a cotton-
tipped applicator. The sample was smeared over a standard
glass slide, fixed, stained, and immediately examined to count
the eosinophils. The proportion of eosinophils was expressed
as a percentage of the total non-squamous cell count. 
Sinus radiography
Waters’ view, Candler’s view, and skull lateral view were
taken.
Spirometry
Spirometry was performed according to American Thoracic
Society standards (7) using SensorMedics 2200 spirometer
(Cardiopulmonary Care CompanyTM, Yorba Linda, California).
The representative values for forced vital capacity (FVC) and
forced expiratory volume in one second (FEV1) were selected
according to International Thoracic Society criteria (8), and
the reference values were taken from the reports by Choi et al.
(9) and by Kim et al. (10). 
Bronchial hyperresponsiveness 
Methacholine challenge tests were carried out by a modified
method described by Chai et al. (11), and were performed in
the pollen season. Concentrations of 0.075, 0.15, 0.31, 0.62,
1.25, 2.5, 5, 10, and 25 mg/mL methacholine were prepared
by dilution with buffered saline. A Micro-dosimeter (S&M
Instrument Co, Doylestown, PA) was used to deliver the aerosol
generated by a DeVilbiss 646 nebulizer (Sunrise Medical
HHG., Inc., Pittsburgh, PA, U.S.A.). Subjects inhaled 5
breaths of increasing concentrations of methacholine until
FEV1 fell by more than 20% of its basal value or it reached
the highest concentration level. The largest value of triplicate
FEV1 at 30, 90 or 180 sec after each inhalation was adopted
for analysis. If PC20 was less than 25 mg/mL, a subject was
considered to have BHR to methacholine. 
Allegy skin prick tests
Allergy skin prick tests were performed using 55 common
allergen extracts (Allergopharma Co, Germany). None of the
subjects had received antihistamines orally for 3 days preceding
the study. A positive control of histamine (1 mg/mL) along
with a negative diluent control was included in all tests. After
15 min, the mean diameter of a wheal formed by the allergen
was compared with that formed by histamine. If the former
was same or larger than the latter (A/H ratio ≥1.0), the reac-
tion was deemed to be positive. Atopy means one or more
positive allergy prick tests.
Blood sampling
Venous blood was collected into the tubes containing 5.0 mL
ethylenediaminetetraacetic acid (K3 Vacutainer BD, Ruther-
fold, N.J.) simultaneously with nasal smear, differential white
blood cell count was obtained using of a Coulter STKS instru-
ment (Coulter Corp., Hialeah, Fla.). The total serum IgE was
measured by enzyme immunoassay.    
Statistical analysis
All data were analyzed using the SPSS version 7.5 for Win-
dows. Data are expressed as mean±SEM. Comparison of con-
tinuous variables was performed using chi-square test, Fisher’s
exact test, and Mann-Whitney U test. Spearman’s correlations
were used to assess relationships between variables. A p-value of
<0.05 was considered significant.
RESULTS
The characteristics of 35 patients (13 perennial AR with
exacerbation and 22 seasonal AR) enrolled to the study are
given in Table 1. Seasonal AR patients were positive in alder,
birch, hazel, rye, timothy, mugwort, ragweed allergens. 
Symptom scores
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nasal obstruction were 2.17, 2.11, 2.31, and 2.25, respectively
(2.17±1.03 vs. 2.11±1.21 vs 2.31±1.10 vs 2.25±1.03).
Nasal obstruction scores were higher in patients with perennial
AR with exacerbation than in patients with seasonal AR (2.76
±0.28 vs 1.95±0.20, p<0.05). 
Nasal eosinophils, IgE, blood eosinophils
The level of total IgE was higher in patients with seasonal
AR than in patients with perennial AR with exacerbation
(472.5±132.5 IU/L vs 389.0±70.9 IU/L, p<0.05). Nasal
eosinophils were 31.7±5.1% (0-95%). There were no differ-
ences of nasal eosinophils between perennial and seasonal AR
(26.3±6.5% vs 34.8±7.3%). PC20 was lower in patients
with >10% of nasal eosinophils than in patients with <10%
of nasal eosinophils (4.06±1.36 vs 8.02±3.73). However,
nasal eosinophils were closely related to log PC20 (Fig. 1, r=
-0.65, p<0.01). There were no correlations between symp-
tom scores and nasal eosinophils.
Bronchial hyperresponsiveness
Twenty-two patients had BHR. No significant differences
in BHR were detected in the comparison of patients with and
without cough, and of patients with and without postnasal
drip. Significant differences in BHR were detected in the com-
parison of patients with cough or postnasal drip, and without
cough or postnasal drip (Table 2, p<0.01). There were signif-
icant differences of PC20 in patients between with cough or
postnasal drip, and without cough or postnasal drip (3.41±
3.59 mg/mL vs 10.2±1.2 mg/mL, p=0.001). 
DISCUSSION
The present study showed that nasal eosinophils were corre-
lated with BHR, suggesting that upper airway eosinophilic
inflammation contributes to BHR. 
There is a link between AR and asthma. Asthma and rhinitis
can be associated with both an IgE-mediated allergic reaction
and an inflammatory pattern. Twenty eight to fifty percent of
asthmatic patients has AR, compared to 10-20% in the general
population. Many patients with AR who have no perceived
asthma symptoms have BHR to natural stimuli, such as exercise
or to bronchial challenge with chemical stimuli, such as his-
tamine and methacholine, especially during AR exacerbation
(3). Simons (12) suggested that the new term “allergic rhino-
bronchitis” accurately describes chronic allergic inflammation
throughout the airways of patients with concurrent AR and
asthma. He recommended, the key to management of both
disorders lies in addressing the common immunopathologic
mechanisms and in preventing and relieving chronic allergic
inflammation, not only with appropriate pharmacologic treat-
ment, but also by recommending allergen avoidance and in
selected patients, specific immunotherapy. In this study nasal
eosinophils were related to BHR, suggesting that the common
immunopathologic mechanisms of upper and lower airway
inflammation may occur. 
AR is characterized by the temporal relationship of symp-
toms to allergen exposure such as dust mites, pollens, animal
dander, and mold spores. Symptom scores may provide a com-
prehensive picture of airway disease for quality assurance or
Cough or Postnasal drip  Yes          17             2
No           5             11
Table 2. Relationship of bronchial hyperresponsiveness and
cough or postnasal drip
Bronchial hyperresponsiveness 
Yes  No
























Fig. 1. Correlations between nasal eosinophils and bronchial
hyperresponsiveness. PC20 values expressed as milligrams per
milliter of methacholine. 
r=-0.65
p<0.01
0      10      20      30      40      50      60      70      90      100
Age(yr)             33.5±3.2 29.9±2.4
Male/Female          8/5  13/9 
IgE                 157.8±74.3 389.0±70.9*
Serum-eosinophils      472.5±132.5 538.9±166.9 
Nasal symptom score
Itching            2.23±0.34 2.04±0.25
Sneezing          2.30±0.26 2.09±0.18 
Coryza            2.23±0.28 2.36±0.25
Obstruction        2.76±0.28
� 1.95±0.20  
PC20 (mg/mL)            5.20±2.7 4.80±1.60
Perennial Seasonal
*p<0.05 compared with perennial allergic rhinitis with exacerbation, 
� p<
0.05 compared with seasonal allergic rhinitis.
PC20 were defined as the methacholine concentration causing a 20%
fall in FEV1.
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research purpose (13). Bousquet et al. (14) demonstrated that
quality of life was more affected by rhinoconjuctivitis than by
asthma symptoms. Nasal obstruction scores were higher in
patients with perennial AR with exacerbation than in patients
with seasonal AR, indicating that airway passage be more affect-
edin perennial AR.
The underlying pathologic processes are similar in the upper
and lower airways. Patients with grass pollen allergy develop
a moderate hyposmia during 3 weeks of natural grass pollen
exposure. This is better correlated with inflammatory mediators
such as eosinophilic cationic protein in the nasal secretion level
than with nasal air flow measured by active anterior rhino-
manometry (15). Immune effector cells responsible for allergic
reactions in both the lung and the nose include, most promi-
nently, mast cell, T lymphocytes, and eosinophils (16-18).
Eosinophils are characteristics for acute and chronic inflam-
matory changes observed in bronchial asthma and AR, and
have also been implicated in many aspects of tissue damage
that occurs at sites of chronic inflammation. In this study there
are no differences of nasal eosinophils between perennial and
seasonal AR. 
AR patients who were hyperresponsive to methacholine were
at significantly greater risk of developing asthma than those
with normal bronchial challenge (19). Upper airway inflam-
matory processes occurring totally or primarily in the upper
airway may participate in the pathogenesis of BHR and asthma
(20). Perennial rhinitis is much more important than seasonal
rhinitis as a risk factor for developing nonspecific BHR (21). In
contrary to that study, we had no differences of BHR between
seasonal and perennial AR in this study. Further follow up
studies are needed to clarify risk factor for developing bronchial
asthma. Rhinitis subjects with nonspecific hyperresponsiveness
develop asthma more frequently than those without (3, 19).
Inflammatory cells are present, not only in the airways of pa-
tients with asthma but also, in airways of patients with seasonal
AR, even outside natural exposure. 
In summary, the present study shows that there is a rela-
tionship of nasal eosinophils and BHR, suggesting that nasal
eosinophils may play a role in the development of BHR in
rhinitis patients. 
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